Compound Radar

Alkermes plc (ALKS) Stock Analysis

Price $45.49
Market cap $7.63B
Next earnings Oct 28, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

62
62/100 Good Quality
  • Financial Health 75
  • Profitability 40
  • Business Quality 75
  • Balance Sheet 40
  • Cash Flow 70

Why this rating?

Health 62/100 — Good Quality

Strongest Financial Health 75/100
Softest Balance Sheet 40/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Alkermes plc (ALKS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Alkermes plc 62/100 (Good Quality) due to high business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality High
  • Growth Strong
  • Balance Sheet Stretched
  • Valuation Fair

Financial highlights

Valuation

  • P/E 119.71
  • Forward P/E 24.88
  • PEG 1.96
  • EV/Revenue 5.19

Profitability

  • Revenue Growth 27.0%
  • Gross Margin 87.2%
  • Operating Margin 15.5%
  • Net Margin 4.0%
  • ROE 3.9%

Financial strength

  • Cash $656.58M
  • Debt $1.57B
  • Net Cash $-915.99M
  • Free Cash Flow $480.33M
  • Current Ratio 2.3

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Alkermes plc (ALKS).

View Methodology & FAQ →